159 related articles for article (PubMed ID: 30643090)
21. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
[TBL] [Abstract][Full Text] [Related]
22. Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes.
Takada A; Katashima M; Kaibara A; Sawamoto T; Zhang W; Keirns J
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):365-70. PubMed ID: 27129009
[TBL] [Abstract][Full Text] [Related]
23. Aseptic Meningitis after Amenamevir Treatment for Herpes Zoster in the First Branch of the Trigeminal Nerve.
Itoh K; Mitsuke Y; Wakahara M; Yoshioka T; Otsuki N; Suzuki Y; Kiriba C; Kuwata A; Sakamaki I; Iwasaki H; Tsutani H
Intern Med; 2022 Sep; 61(18):2809-2811. PubMed ID: 35228415
[TBL] [Abstract][Full Text] [Related]
24. Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations.
Mercier-Darty M; Boutolleau D; Lepeule R; Rodriguez C; Burrel S
Antiviral Res; 2018 Mar; 151():20-23. PubMed ID: 29337163
[TBL] [Abstract][Full Text] [Related]
25. [Varicella-zoster meningoencephalitis and vasculitis after treatment with amenamevir to herpes zoster in the trigeminal nerve area].
Taniguchi Y; Kano Y; Kitamura T; Miura T; Yamada K
Rinsho Shinkeigaku; 2021 Apr; 61(4):239-242. PubMed ID: 33762495
[TBL] [Abstract][Full Text] [Related]
26. Advances and Perspectives in the Management of Varicella-Zoster Virus Infections.
Andrei G; Snoeck R
Molecules; 2021 Feb; 26(4):. PubMed ID: 33672709
[TBL] [Abstract][Full Text] [Related]
27. Recent topics in the management of herpes zoster.
Asada H
J Dermatol; 2023 Mar; 50(3):305-310. PubMed ID: 36539935
[TBL] [Abstract][Full Text] [Related]
28. Advances in the treatment of varicella-zoster virus infections.
Andrei G; Snoeck R
Adv Pharmacol; 2013; 67():107-68. PubMed ID: 23886000
[TBL] [Abstract][Full Text] [Related]
29. Antiviral therapy of herpes simplex and varicella-zoster virus infections.
Wutzler P
Intervirology; 1997; 40(5-6):343-56. PubMed ID: 9675639
[TBL] [Abstract][Full Text] [Related]
30. Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents.
Ohtsu Y; Susaki Y; Noguchi K
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):693-706. PubMed ID: 29748821
[TBL] [Abstract][Full Text] [Related]
31. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial.
Shafran SD; Tyring SK; Ashton R; Decroix J; Forszpaniak C; Wade A; Paulet C; Candaele D
J Clin Virol; 2004 Apr; 29(4):248-53. PubMed ID: 15018852
[TBL] [Abstract][Full Text] [Related]
32. Varicella-Zoster Meningitis and Myelitis After Herpes Zoster Dermatitis Treatment With Amenamevir: A Case Series and Literature Review.
Tada S; Kaito Y; Watanabe A; Sugiyama Y; Nishigaichi A; Miwa T; Watanabe K; Hazama T; Takahashi D
Cureus; 2024 Feb; 16(2):e54775. PubMed ID: 38524092
[TBL] [Abstract][Full Text] [Related]
33. Varicella zoster virus: natural history and current therapies of varicella and herpes zoster.
Breuer J; Whitley R
Herpes; 2007 Sep; 14 Suppl 2():25-9. PubMed ID: 17939892
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory effect of amenamevir on acute herpetic pain and postherpetic neuralgia in mice infected with herpes simplex virus-1.
Ueda Y; Uta D; Tanbo S; Kawabata A; Kanayama S; Osaki M; Nozawa N; Matsumoto T; Andoh T
J Dermatol Sci; 2020 Apr; 98(1):50-57. PubMed ID: 32284168
[TBL] [Abstract][Full Text] [Related]
35. Improvement of acyclovir-resistant herpes zoster infection by amenamevir.
Onaka T; Shiraki K; Yonezawa A
J Dermatol; 2021 Sep; 48(9):e478-e479. PubMed ID: 34137062
[No Abstract] [Full Text] [Related]
36. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial.
Tyring SK; Plunkett S; Scribner AR; Broker RE; Herrod JN; Handke LT; Wise JM; Martin PA;
J Med Virol; 2012 Aug; 84(8):1224-32. PubMed ID: 22711350
[TBL] [Abstract][Full Text] [Related]
37. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster.
Lin WR; Lin HH; Lee SS; Tsai HC; Huang CK; Wann SR; Chen YS; Chiang SC; Yen MY; Liu YC
J Microbiol Immunol Infect; 2001 Jun; 34(2):138-42. PubMed ID: 11456360
[TBL] [Abstract][Full Text] [Related]
38. Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older.
Madkan VK; Arora A; Babb-Tarbox M; Aboutlabeti S; Tyring S
J Cutan Med Surg; 2007; 11(3):89-98. PubMed ID: 17511925
[TBL] [Abstract][Full Text] [Related]
39. Herpes simplex virus and varicella zoster virus: recent advances in therapy.
De SK; Hart JC; Breuer J
Curr Opin Infect Dis; 2015 Dec; 28(6):589-95. PubMed ID: 26524331
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus.
Colin J; Prisant O; Cochener B; Lescale O; Rolland B; Hoang-Xuan T
Ophthalmology; 2000 Aug; 107(8):1507-11. PubMed ID: 10919899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
